应用微阵列分析技术对胃癌基因组的相关性研究
发布时间:2018-05-15 11:48
本文选题:胃癌 + 全基因组微阵列分析 ; 参考:《吉林大学》2015年硕士论文
【摘要】:背景:随着医疗技术的发展和人们的逐渐重视,胃癌的早期诊断率有所增加,治疗方法日益完善,但尽管采用手术、化疗和放疗等综合措施治疗胃癌,对晚期胃癌患者的整体效果仍不甚满意。肿瘤是多基因病,肿瘤的全基因组研究逐渐被人们所重视,明确肿瘤细胞的基因结构,干预细胞的基因表达过程,是肿瘤治疗研究的重要方向。目前,对于胃癌的全基因组研究较少,基因治疗效果局限。微阵列分析可以大规模的分析基因组数据,,明确胃癌基因组的异常变化,以达到个性化治疗的目的。 目的:通过对胃癌标本进行全基因组高分辨率微阵列分析,明确胃癌染色体组基因拷贝数异常以及杂合子缺失情况,分析其发生变化区域所包含的肿瘤相关基因,为早期诊断提供新标志物,同时为基因治疗提供新靶点。 方法:本实验收集附属医院综合临床、影像学及术后病理明确诊断为胃癌的组织标本,提取其DNA,通过应用CGH+SNP芯片的全基因组高分辨率微阵列分析技术,分析胃癌基因组的染色体拷贝数异常及杂合子缺失情况,明确其与胃癌的相关性,为提出新的肿瘤标志物以及个性化基因治疗做铺垫。 结果:35例胃癌标本均有复杂的拷贝数丢失和(或)扩增以及杂合子缺失情况,其中胃癌DNA1p,3p,4p,5q,6q,8p,9p,10q,11q,14q,15q,16q,17p,18p,19p,21q,22q,WholeY均存在基因拷贝数丢失,1q,3q,5p,6p,7p,8q,9q,11p,12q,13q,17q,19q,20q,Xq存在基因拷贝数扩增。50%以上的病例发现8q24.11q24.21,8q24.21q24.22,8q24.3的拷贝数扩增,45%的病例存在3p14.2拷贝数丢失,多例标本发现20号染色体整条拷贝数扩增及Y号染色体整条拷贝数丢失,是进一步研究的新方向。同时发现一些肿瘤相关基因如FHIT、APC、DCC、WWOX等基因拷贝数丢失,以及CDKs、EGFR、PIK3CA等基因的染色体拷贝数扩增与胃癌相关性大,并发现其他肿瘤相关基因MTAP、NDUFA13等基因拷贝数的丢失以及SET、RAP2B、SRC等基因拷贝数的扩增与胃癌有相关性,目前这些基因与胃癌相关研究较少,可作为进一步研究的方向。虽多例胃癌标本DNA均存在杂合子缺失,但其中所发现有意义的基因较少,PAX1有研究表明与乳腺癌相关,可在将来结合胃癌的分组进一步做相关研究。 结论: 1、胃癌DNA1p,3p,4p,5q,6q,8p,9p,10q,11q,14q,15q,16q,17p,18p,19p,21q,22q,WholeY均存在基因拷贝数丢失,1q,3q,5p,6p,7p,8q,9q,11p,12q,13q,17q,19q,20q,Xq存在基因拷贝数扩增。其中50%以上的病例发现8q24.11q24.21,8q24.21q24.22,8q24.3的拷贝数扩增,45%的病例存在3p14.2拷贝数丢失,多例标本发现20号染色体整条拷贝数扩增及Y号染色体整条拷贝数丢失,是进一步研究的新方向。 2、发现FHIT、APC、DCC、WWOX等基因拷贝数丢失,以及CDKs、EGFR、PIK3CA等基因的染色体拷贝数扩增与胃癌相关性较高。 3、发现其他肿瘤相关基因MTAP、NDUFA13等基因拷贝数的丢失以及SET、RAP2B、SRC等基因拷贝数的扩增与胃癌有相关性,是胃癌基因学研究的新方向。
[Abstract]:Background: with the development of medical technology and people's attention gradually, the early diagnosis rate of gastric cancer has increased and the treatment method has been improved. However, although comprehensive measures such as surgery, chemotherapy and radiotherapy are used to treat gastric cancer, The overall effect on patients with advanced gastric cancer is still not satisfactory. Tumor is a polygenic disease, and the whole genome of tumor has been paid more and more attention. It is an important direction of tumor therapy to clarify the gene structure of tumor cells and interfere with the gene expression process of tumor cells. At present, there is little research on the whole genome of gastric cancer, and the effect of gene therapy is limited. Microarray analysis can analyze genomic data on a large scale and identify abnormal changes of gastric cancer genome in order to achieve individualized treatment. Objective: to identify the aberrant copy number and heterozygote deletion of the chromosomes of gastric cancer samples by high resolution microarray analysis of the whole genome, and to analyze the tumor-related genes contained in the region in which they change. To provide a new marker for early diagnosis and a new target for gene therapy. Methods: the tissue samples from general clinical, imaging and postoperative pathological diagnosis of gastric cancer in affiliated hospitals were collected, and their DNA was extracted. The whole genome microarray technique was used to analyze the DNA of gastric cancer by using CGH SNP chip. The chromosome copy number abnormality and heterozygote deletion in the genome of gastric cancer were analyzed, and the correlation between them and gastric cancer was clarified, which paved the way for the development of new tumor markers and personalized gene therapy. Results all 35 cases of gastric cancer had complicated copy loss and / or amplification and heterozygote deletion. 鍏朵腑鑳冪檶DNA1p,3p,4p,5q,6q,8p,9p,10q,11q,14q,15q,16q,17p,18p,19p,21q,22q,WholeY鍧囧瓨鍦ㄥ熀鍥犳嫹璐濇暟涓㈠け,1q,3q,5p,6p,7p,8q,9q,11p,12q,13q,17q,19q,20q,Xq瀛樺湪鍩哄洜鎷疯礉鏁版墿澧
本文编号:1892344
本文链接:https://www.wllwen.com/yixuelunwen/zlx/1892344.html